Senseonics
20451 Seneca Meadows Parkway
Germantown
Maryland
20876-7005
United States
Tel: 301-515-7260
Fax: 301-515-0988
Website: http://senseonics.com/
About Senseonics
We are a medical technology company focused on the design, development and commercialization of glucose monitoring systems to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Our first generation continuous glucose monitoring, or CGM, system is a reliable, long-term, implantable CGM system that we have designed to continually and accurately measure glucose levels in people with diabetes for a period of up to 90 days, as compared to five to seven days for currently available CGM systems.YEAR FOUNDED:
1996
LEADERSHIP:
CEO: Timothy T. Goodnow, PhD
CFO: R. Don Elsey
Chief Medical Officer: E. Lynne Kelley, M.D., FACS
162 articles about Senseonics
-
Senseonics Holdings, Inc. Announces Data From the Eversense® Post Approval Study to Be Presented at the 17th International Conference on Advanced Technologies and Treatments for Diabetes
3/8/2024
Senseonics Holdings, Inc. Announces Data From the Eversense ® Post Approval Study to Be Presented at the 17th International Conference on Advanced Technologies and Treatments for Diabetes.
-
Senseonics Holdings, Inc. to Participate in the Oppenheimer 34th Annual Healthcare MedTech and Services Conference
3/6/2024
Senseonics Holdings, Inc. to Participate in the Oppenheimer 34th Annual Healthcare MedTech and Services Conference.
-
Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
2/29/2024
Senseonics Holdings, Inc., a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring systems for people with diabetes, reported financial results for the quarter and full year ended December 31, 2023.
-
Senseonics Holdings, Inc. Schedules Fourth Quarter and Full Year 2023 Earnings Release and Conference Call for February 29, 2024 at 4:30 P.M. Eastern Time
2/15/2024
Senseonics Holdings, Inc. announced that it plans to release its fourth quarter and full year 2023 financial results after market close on Thursday, February 29, 2024.
-
PHC Holdings Corporation and Senseonics Announce Appointment of Brian Hansen as President of CGM at Ascensia Diabetes Care
2/6/2024
PHC Holdings Corporation and Senseonics Announce Appointment of Brian Hansen as President of CGM at Ascensia Diabetes Care.
-
Senseonics Holdings, Inc. Announces Business Updates - Jan 02, 2024
1/2/2024
Senseonics Holdings, Inc., a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring systems for people with diabetes, announced operational and financial business updates.
-
Senseonics Holdings, Inc. to Participate in the Stifel 2023 Healthcare Conference
11/9/2023
Senseonics Holdings, Inc. today announced plans to participate in the upcoming Stifel 2023 Healthcare Conference, taking place in New York, NY.
-
Senseonics Holdings, Inc. Reports Third Quarter 2023 Financial Results
11/9/2023
Senseonics Holdings, Inc., a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring systems for people with diabetes, reported financial results for the quarter ended September 30, 2023.
-
Senseonics Holdings, Inc Schedules Third Quarter 2023 Earnings Release and Conference Call for November 9, 2023 at 4:30 p.m. Eastern Time
10/30/2023
Senseonics Holdings, Inc. announced that it plans to release its third quarter 2023 financial results after market close on Thursday, November 9, 2023.
-
Ascensia Diabetes Care and Senseonics Announce 'The CGM for Real Life' Campaign to Raise Awareness of How Long-Term Eversense E3 Empowers People with Diabetes
10/9/2023
Ascensia Diabetes Care and Senseonics Holdings, Inc. have launched a new U.S. advertising and marketing campaign for Eversense® E3 CGM System.
-
Senseonics Announces the Last Patient Completion of the 365-Day ENHANCE Pivotal Clinical Study
9/26/2023
Senseonics Holdings, Inc. today announced the completion of the ENHANCE Pivotal Clinical Study adult cohort following the recently completed 365-day visit for the final study patient.
-
Senseonics Holdings, Inc. to Participate in the Gilmartin Group Emerging Growth Company Showcase
9/14/2023
Senseonics Holdings, Inc. today announced plans to participate in the upcoming Gilmartin Group Emerging Growth Company Showcase, taking place virtually.
-
Senseonics Holdings, Inc. Enters Into $50 Million Loan Facility With Hercules Capital
9/11/2023
Senseonics Holdings, Inc., a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring systems for people with diabetes, announced that it has entered into a $50 million loan facility with Hercules Capital, Inc.
-
Senseonics Holdings, Inc. Reports Second Quarter 2023 Financial Results
8/10/2023
Senseonics Holdings, Inc., a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring systems for people with diabetes, reported financial results for the quarter ended June 30, 2023.
-
Senseonics Holdings, Inc. Schedules Second Quarter 2023 Earnings Release and Conference Call for August 10, 2023 at 4:30 p.m. Eastern Time
7/27/2023
Senseonics Holdings, Inc. announced that it plans to release its second quarter 2023 financial results after market close on Thursday, August 10, 2023.
-
Senseonics Announces Equity Grants To Employees Under Inducement Plan - July 05, 2023
7/5/2023
Senseonics Holdings, Inc., a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring systems for people with diabetes, announced that it had made equity grants to new employees under its 2019 Inducement Plan in accordance with NYSE American Company Guide Section 711.
-
New Clinical Data Demonstrating the Safety and Accuracy of Eversense through 365 Days Presented at the American Diabetes Association 83rd Scientific Sessions
6/26/2023
New Clinical Data Demonstrating the Safety and Accuracy of Eversense through 365 Days Presented at the American Diabetes Association 83rd Scientific Sessions.
-
Senseonics Announces UnitedHealthcare Coverage of Eversense® E3 CGM for Adults with Diabetes
6/2/2023
Senseonics Announces UnitedHealthcare Coverage of Eversense® E3 CGM for Adults with Diabetes.
-
Senseonics to Participate in the Jefferies 2023 Healthcare Conference
5/26/2023
Senseonics Holdings, Inc. announced plans to participate in the upcoming Jefferies Healthcare Conference in New York, NY.
-
Senseonics Holdings, Inc. Schedules First Quarter 2023 Earnings Release and Conference Call for May 9, 2023, at 4:30 p.m. Eastern Time
4/27/2023
Senseonics Holdings, Inc. announced that it plans to release its first quarter 2023 financial results after market close on Tuesday, May 9, 2023.